Home / News

2025-12-15: Keythera Pharma | KF-0210 Delivers Rapid, Deep, and Durable Sym...

Suzhou — Keythera Pharma today announced positive results from a Phase IIa exploratory study of KF-0210, the first oral EP4 antagonist to enter human...

2020-12-10

Keythera won New Bud Award 2020 Venture Top 50

After 8-month evaluation, the 2020 Venture Top 50 list was finally unveiled. Richland Equities series enterprise Keythera Biopharmaceuticals won the honor on the top 50 New Bud List!...

More >>

2020-09-28

Keythera completed RMB 100M Series A financing

Recently, Keythera (Suzhou) Biopharmaceutical Co., Ltd., an innovative drug research and development enterprise, announced the completion of a Series A financing of nearly RMB 100 million....

More >>

Home
Before
1
2
Next
Back